Analysis of clinical and molecular associations of triple negative breast cancers in node-negative patients

European Journal of Gynaecological Oncology

Volumn 31, Issue 3, 2010, Pages 304-307

  Koronakis, N ^b   Karanikas, G ^b   Lagoudianakis, E E ^a   Grosomanidis, D ^b   Pappas, A ^a   Chrysikos, J ^b   Xepapadakis, G ^b   Manouras, A ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b IASO   (Greece)

Author keywords

EGFR expression; Molecular profile; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PATIENT; CONTROLLED STUDY; FEMALE; GREECE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MITOSIS RATE; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77954098794     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J.: "Cancer statistics, 2008". Cancer J. Clin., 2008, 58, 71.
2. Berry D.A., Cronin K.A., Plevritis S.K., Fryback D.G., Clarke L., Zelen M. et. al.: "Effect of screening and adjuvant therapy on mortality from breast cancer". N. Engl. J. Med., 2005, 353, 1784. (Pubitemid 41549890)
3. Muñoz M., Estévez L.G., Alvarez I., Fernández Y., Margelí M., Tusquets I. et al.: "Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer". Cancer Treat. Rev., 2008, 34, 701.
4. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J. et al.: "Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer". JAMA, 2006, 295, 1658.
5. Cole B.F., Gelber R.D., Gelber S., Coates A.S., Goldhirsch A.: "Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis". Lancet, 2001, 358, 277. (Pubitemid 32738966)
6. Soerjomataram I., Louwman M.W., Ribot J.G., Roukema J.A., Coebergh J.W.: "An overview of prognostic factors for long-term survivors of breast cancer". Breast Cancer Res. Treat., 2008, 107, 309. (Pubitemid 351172108)
7. Acharya C.R., Hsu D.S., Anders C.K., Anguiano A., Salter K.H., Walters K.S. et al.: "Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer". JAMA. 2008, 299, 1574.
8. Marchionni L., Wilson R.F., Wolff A.C., Marinopoulos S., Parmigiam G., Bass E.B., Goodman S.N.: "Systematic review: gene expression profiling assays in early-stage breast cancer". Ann. Intern. Med., 2008, 148, 358.
9. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A. et al.: "Molecular portraits of human breast tumours". Nature, 2000, 406, 747.
10. Livasy C.A., Karaca G., Nanda R., Tretiakova M.S., Olopade O.I., Moore D.T., Perou C.M.: "Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma". Mod. Pathol., 2006, 19, 264.
11. Nielsen T.O., Hsu F.D., Jensen K., Cheang M., Karaca G., Hu Z. et al.: "Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma". Clin. Cancer Res., 2004, 10, 5367.
12. Kassam F., Enright K., Dent R., Dranitsaris G., Myers J., Flynn C. et al.: "Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design". Clin. Breast. Cancer, 2009, 9, 29.
13. Voduc D., Nielsen T.O.: "Basal and triple-negative breast cancers: impact on clinical decision-making and novel therapeutic options". Clin. Breast. Cancer, 2008, 8 (suppl. 4), S171.
14. Anders C., Carey L.A.: "Understanding and treating triple-negative breast cancer". Oncology (Williston Park), 2008, 22, 1233.
15. Petit T., Wilt M., Velten M., Millon R., Rodier J.F., Borel C. et al.: "Comparative value of tumor grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy". Eur. J. Cancer, 2004, 40, 205.
16. Leitzel K., Teramoto Y., Konrad K., Chinchilli V., Engle L., Harvey H.A. et al.: "Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer". J. Clin. Oncol., 1995, 13, 1129.
17. Rakha E.A., El-Sayed M.E., Lee A.H., Elston C.W., Grainge M.J., Hodi Z. et al.: "Prognostic significance of nottingham histologic grade in invasive breast carcinoma". J. Clin. Oncol., 2008, 26, 3153.
18. Baak J.P., Gudlaugsson E., Skaland I., Guo L.H., Klos J., Lende T.H. et al.: "Proliferation is the strongest prognosticator in node-negative breast cancer: significance, error sources, alternatives and comparison with molecular prognostic markers". Breast Cancer Res. Treat., 2009, 115, 241.
19. van Diest P.J., van der W.E., Baak J.P.: "Prognostic value of proliferation in invasive breast cancer: a review". J. Clin. Pathol., 2004, 57, 675.
20. Fulford L.G., Easton D.F., Reis-Filho J.S., Sofronis A., Gillet C.E., Lakhani S.R., Hanby A. et al.: "Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast". Histopathology, 2006, 49, 22.
21. Rhee J., Han S.W., Oh D.Y., Kim J.H., Im S.A., Han W. et al.: "The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer". B.M.C. Cancer, 2008, 8, 307.
22. Callagy G.M., Pharoah P.D., Pinder S.E., Hsu F.D., Nielsen T.O., Ragaz J. et al.: "Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index". Clin. Cancer Res., 2006, 12, 2468.
23. Callagy G.M., Webber M.J., Pharoah P.D., Caldas C.: "Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer". B.M.C. Cancer, 2008, 8, 153.
24. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J.A., Rampaul R.S., Blarney R.W. et al.: "Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma". Br. J. Cancer, 2004, 91, 1532.
25. Rocha-Lima C.M., Soares H.P., Raez L.E., Singal R.: "EGFR targeting of solid tumors". Cancer Control, 2007, 14, 295.
26. Siziopikou K.P., Cobleigh M.: "The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies". Breast., 2007, 16, 104.
27. Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H., Robertson J.F., Ellis I.O.: "Prognostic markers in triple-negative breast cancer". Cancer, 2007, 109, 25.
28. Umemura S., Takekoshi S., Suzuki Y., Saitoh Y., Tokuda Y., Osamura R.Y.: "Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression". Oncol. Rep., 2005, 14, 337.
29. Chae B.J., Bae J.S., Lee A., Park W.C., Seo Y.J., Song B.J. et al.: "p53 as a specific prognostic factor in triple-negative breast cancer". Jpn. J. Clin. Oncol., 2009, 39, 217.
30. Pharoah P.D., Day N.E., Caldas C.: "Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis". Br. J. Cancer, 1999, 80, 1968.
31. Reed W., Hannisdal E., Boehler P.J., Gundersen S., Host H., Marthin J.: "The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years". Cancer, 2000, 88, 804.
32. Ko S.S., Na Y.S., Yoon C.S., Park J.Y., Kim H.S., Hur M.H. et al.: "The significance of c-erbB-2 overexpression and p53 expression in patients with axillary lymph node-negative breast cancer: a tissue microarray study". Int. J. Surg. Pathol., 2007, 15, 98.
33. Geisler S., Børresen-Dale A.L., Johnsen H., Aas T., Geisler J., Akslen L.A., Anker G., Lønning P.E.: "TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer". Clin. Cancer Res., 2003, 9, 5582.